Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Staphylokinase]

G Helft1, J Lebrazi, I Elalamy

  • 1Clinique Cardiologique, Hôpital Necker, Paris.

Annales De Cardiologie Et D'Angeiologie
|November 11, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[stent thrombosis : A won battle ? (data from the France PCI registry)].

Annales de cardiologie et d'angeiologie·2021
Same author

Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: "OLTAT registry".

International journal of cardiology·2018
Same author

[Characteristics and management of ST-elevation myocardial infarction in France: Regional variations in 2010].

Annales de cardiologie et d'angeiologie·2015
Same author

[Cardiovascular involvement in Behçet's disease].

La Revue de medecine interne·2014
Same author

Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.

Thrombosis and haemostasis·2013
Same author

Allelic variations of the vitamin D receptor (VDR) gene are associated with increased risk of coronary artery disease in type 2 diabetics: the DIABHYCAR prospective study.

Diabetes & metabolism·2013
Same journal

[Study of Sleep Apnea Syndrome in Patients with Chronic Heart Failure in the Cardiology Department at Yalgado Ouédraogo teaching hospital in 2024 and 2025].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Impact of knowledge and practices of hygieno-dietetical measures in hypertensive people at the Abidjan cardiology institute].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Correlation between carotid atheroma and DAS28 gamma GT score in rheumatoid arthritis in an African black population].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Dobutamine stress echocardiography: Appropriateness of indications and protocol compliance. A single-centre report].

Annales de cardiologie et d'angeiologie·2026
Same journal

[Post-COVID postural orthostatic tachycardia syndrome: Documentation of a hyperadrenergic phenotype by comprehensive autonomic testing].

Annales de cardiologie et d'angeiologie·2026
Same journal

Urban-rural disparities in hypertension prevalence, screening, and control in South Kivu Province, eastern Democratic Republic of the Congo.

Annales de cardiologie et d'angeiologie·2026
See all related articles

Staphylokinase, a third-generation thrombolytic agent, shows promise for improving myocardial infarction treatment by enhancing arterial patency and reducing reocclusions and severe complications compared to current therapies.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Context:

  • Myocardial infarction (MI) results from coronary artery thrombotic occlusion.
  • Current thrombolytic agents reduce mortality but have limitations including suboptimal arterial patency (50%), reocclusions (5-10%), and severe complications like cerebral hemorrhages (0.5%).
  • There is a need for improved thrombolytic agents to optimize treatment outcomes for MI patients.

Purpose:

  • To review the characteristics, mechanism of action, and fibrinolytic properties of staphylokinase.
  • To evaluate the efficacy and safety of staphylokinase as a third-generation thrombolytic agent.
  • To present findings from animal models and summarize clinical trials in humans.

Summary:

  • Staphylokinase is a protein with profibrinolytic properties, recognized for over four decades and experiencing renewed research interest.

Related Experiment Videos

  • It is classified as a third-generation thrombolytic agent, offering potential advantages over existing treatments for acute myocardial infarction.
  • This review details staphylokinase's scientific profile, including its mechanism, properties, and clinical performance data from preclinical and human studies.

    • Impact:

    • Staphylokinase represents a potential advancement in thrombolytic therapy for myocardial infarction.
    • Improved efficacy and safety profiles could lead to better patient outcomes and reduced healthcare burdens associated with MI.
    • Further clinical evaluation may establish staphylokinase as a superior therapeutic option for acute thrombotic events.